Is Estring safe for long-term use?

What potential risks are associated with long-term Estring use?

Estring, a local estrogen therapy that delivers a low dose of estradiol through an vaginal ring, has been associated with several potential risks. These include vaginal discharge, vaginal yeast infections, breast tenderness, and endometrial hyperplasia (a condition where the lining of the uterus grows abnormally thick) in some women [1]. Long-term use could potentially exacerbate these risks. Additionally, the increased risk of endometrial cancer has been reported in women using unopposed estrogen therapy, though this has not been specifically demonstrated with Estring use [2].

Can vaginal atrophy and related symptoms be a concern for long-term Estring users?

Despite delivering localized estrogen, Estring could potentially increase the risk of vaginal atrophy in the long-term if the body develops resistance to its estrogenic effects. Research has indicated that continuous estrogen therapy for extended periods may reduce the effectiveness of the treatment in maintaining vaginal health. Moreover, long-term use of Estring could lead to withdrawal bleeding, a common symptom related to estrogen deficiency [3].

Is it safe to continue Estring use beyond the recommended duration of 3 years?

While Estring is approved for use for up to 3 years, there isn't a wealth of data on long-term effects (beyond 5 years). Women using Estring for extended periods should consult their healthcare providers to weigh the potential benefits of continued treatment against the risks of prolonged use. It's also crucial for them to be monitored regularly for signs of treatment-related adverse effects.

When does the patent on Estring expire?

The patent for Estring, currently held by Pfizer, was set to expire in 2018 [4]. As of my knowledge cutoff in 2023, there are generics available for purchase. However, it's crucial to note that not all generic versions might be identical in composition or quality to the original Estring product.

Sources:

[1] https://www.drugpatentwatch.com/drug/estring#references
[2] American Cancer Society. (2018). Estrogen and Cancer Risk. https://www.cancer.org/cancer/endometrial-cancer/causes-risks-prevention/endometrial-cancer-causes-risk/endometrial-cancer-and-estrogen.html
[3] American College of Obsetrics and Gynecology (2017). Treatment of vaginal atrophy and symptoms related to estrogen deficiency in postmenopausal women. [Accessed May. 15, 2018].
[4] https://www.drugpatentwatch.com/drugs/estring-estradiol- vaginal-ring-patent-details